entertainment -WSS

entertainment

author：hotspot 2025-10-01 23:03:02 - browse：1

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

WSS

Colonoscopy at 40? Study finds a possible benefit

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

With trial win, GSK could get blood cancer drug back on market

NIH documents show early flaws of $1.6 billion long Covid program

explore

entertainment

explore

Moonlake's readout produced a cash windfall. Risks remain

HIV drugs protect against transmission, even in unprotected sex

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The story of mRNA: From a loose idea to a tool that may help curb Covid

George Santos makes 1st court appearance after pleading not guilty to 13 counts

See how much Covid

Activists slam private health insurers over coverage restrictions

Disclosing genetic information: not as worrisome as once feared

Duchenne breakthrough therapy leaves behind pioneering families

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

hotspot

With FDA staff opposed to Sarepta therapy, top official intervened

Why we need to separate burnout from moral injury in health care

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Woman returns to dialysis after doctors remove transplanted pig kidney

Cord blood banking comes at a high cost to babies

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Wikipedia

hotspot

knowledge

explore